Managing dyslipidaemia in type 2 diabetes mellitus

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 30, Issue 3, 2016, Pages 431-444

  Szalat, Auryan ^a   Durst, Ronen ^a   Leitersdorf, Eran ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

fibrates; hypertriglyceridemia; insulin resistance; low HDL; PCSK9 inhibitors; statin

Indexed keywords

BILE ACID SEQUESTRANT; EZETIMIBE; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; TRIACYLGLYCEROL; PCSK9 PROTEIN, HUMAN; PROPROTEIN CONVERTASE 9;

BARIATRIC SURGERY; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DIABETIC DYSLIPIDAEMIA; DIET; DISEASE ASSOCIATION; DYSLIPIDEMIA; HUMAN; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PHYSICAL ACTIVITY; REVIEW; SMOKING CESSATION; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION; ANTAGONISTS AND INHIBITORS; BLOOD; COMPLICATION; DIABETES MELLITUS, TYPE 2; DISEASE MANAGEMENT; DYSLIPIDEMIAS; HEALTHY LIFESTYLE;

CHOLESTEROL, HDL; DIABETES MELLITUS, TYPE 2; DISEASE MANAGEMENT; DYSLIPIDEMIAS; HEALTHY LIFESTYLE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PROPROTEIN CONVERTASE 9;

EID: 84971665240     PISSN: 1521690X     EISSN: 15321908     Source Type: Journal    
DOI: 10.1016/j.beem.2016.05.004     Document Type: Review

References (99)

1. [1] Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33), UK prospective diabetes study (UKPDS) group. Lancet 352 (1998), 837–853.
2. [2] Holman, R.R., Paul, S.K., Bethel, M.A., et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359 (2008), 1577–1589.
3. [3] Hayward, R.A., Reaven, P.D., Wiitala, W.L., et al. Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes. N Engl J Med 372 (2015), 2197–2206.
4. [4] Patel, A., MacMahon, S., Chalmers, J., et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358 (2008), 2560–2572.
5. [5] Gerstein, H.C., Miller, M.E., Byington, R.P., et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358 (2008), 2545–2559.
6. [6] Gerstein, H.C., Miller, M.E., Genuth, S., et al. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med 364 (2011), 818–828.
7. [7] Mannucci, E., Dicembrini, I., Lauria, A., et al. Is glucose control important for prevention of cardiovascular disease in diabetes?. Diabetes Care 36:Suppl 2 (2013), S259–S263.
8. [8] Kannel, W.B., Lipids, diabetes, and coronary heart disease: insights from the Framingham study. Am Heart J 110 (1985), 1100–1107.
9. [9] Jacobs, M.J., Kleisli, T., Pio, J.R., et al. Prevalence and control of dyslipidaemia among persons with diabetes in the United States. Diabetes Res Clin Pract 70 (2005), 263–269.
10. [10] U.K. Prospective Diabetes Study 27, Plasma lipids and lipoproteins at diagnosis of NIDDM by age and sex. Diabetes Care 20 (1997), 1683–1687.
11. Taskinen, M.R., Boren, J., New insights into the pathophysiology of dyslipidaemia in type 2 diabetes. Atherosclerosis 239 (2015), 483–495.
12. [12] Malave, H., Castro, M., Burkle, J., et al. Evaluation of low-density lipoprotein particle number distribution in patients with type 2 diabetes mellitus with low-density lipoprotein cholesterol <50 mg/dl and non-high-density lipoprotein cholesterol <80 mg/dl. Am J Cardiol 110 (2012), 662–665.
13. [13] Do, R., Willer, C.J., Schmidt, E.M., et al. Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet 45 (2013), 1345–1352.
14. [14] Sirtori, C.R., Calabresi, L., Franceschini, G., et al. Cardiovascular status of carriers of the apolipoprotein A-I(Milano) mutant: the Limone sul Garda study. Circulation 103 (2001), 1949–1954.
15. [15] Voight, B.F., Peloso, G.M., Orho-Melander, M., et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet 380 (2012), 572–580.
16. [16] Kingwell, B.A., Chapman, M.J., Kontush, A., et al. HDL-targeted therapies: progress, failures and future. Nat Rev Drug Discov 13 (2014), 445–464.
17. [17] Turner, R.C., Millns, H., Neil, H.A., et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23). BMJ 316 (1998), 823–828.
18. [18] Howard, B.V., Robbins, D.C., Sievers, M.L., et al. LDL cholesterol as a strong predictor of coronary heart disease in diabetic individuals with insulin resistance and low LDL: the strong heart study. Arterioscler Thromb Vasc Biol 20 (2000), 830–835.
19. [19] Varbo, A., Benn, M., Tybjaerg-Hansen, A., et al. Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol 61 (2013), 427–436.
20. [20] Khan, H.A., Sobki, S.H., Khan, S.A., Association between glycaemic control and serum lipids profile in type 2 diabetic patients: HbA1c predicts dyslipidaemia. Clin Exp Med 7 (2007), 24–29.
21. [21] Gatti, A., Maranghi, M., Bacci, S., et al. Poor glycemic control is an independent risk factor for low HDL cholesterol in patients with type 2 diabetes. Diabetes Care 32 (2009), 1550–1552.
22. [22] Adiels, M., Olofsson, S.O., Taskinen, M.R., et al. Overproduction of very low-density lipoproteins is the hallmark of the dyslipidaemia in the metabolic syndrome. Arterioscler Thromb Vasc Biol 28 (2008), 1225–1236.
23. [23] Avramoglu, R.K., Basciano, H., Adeli, K., Lipid and lipoprotein dysregulation in insulin resistant states. Clin Chim Acta 368 (2006), 1–19.
24. [24] Diffenderfer, M.R., Schaefer, E.J., The composition and metabolism of large and small LDL. Curr Opin Lipidol 25 (2014), 221–226.
25. [25] Glass, C.K., Olefsky, J.M., Inflammation and lipid signaling in the etiology of insulin resistance. Cell Metab 15 (2012), 635–645.
26. [26] Standards of medical care in diabetes–2015. Diabetes Care 39:Suppl 1 (2016), S1–S112.
27. [27] Ryden, L., Grant, P.J., Anker, S.D., et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the task force on diabetes, pre-diabetes, and cardiovascular diseases of the european society of cardiology (ESC) and developed in collaboration with the European association for the study of diabetes (EASD). Eur Heart J 34 (2013), 3035–3087.
28. [28] Fox, C.S., Golden, S.H., Anderson, C., et al. Update on prevention of cardiovascular disease in adults with Type 2 Diabetes Mellitus in light of recent evidence: a scientific statement from the American Heart Association and the American diabetes association. Circulation 132 (2015), 691–718.
29. [29] Gepner, A.D., Piper, M.E., Johnson, H.M., et al. Effects of smoking and smoking cessation on lipids and lipoproteins: outcomes from a randomized clinical trial. Am Heart J 161 (2011), 145–151.
30. [30] Clair, C., Rigotti, N.A., Porneala, B., et al. Association of smoking cessation and weight change with cardiovascular disease among adults with and without diabetes. JAMA 309 (2013), 1014–1021.
31. [31] Kelley, G.A., Kelley, K.S., Effects of aerobic exercise on lipids and lipoproteins in adults with type 2 diabetes: a meta-analysis of randomized-controlled trials. Public Health 121 (2007), 643–655.
32. [32] Chudyk, A., Petrella, R.J., Effects of exercise on cardiovascular risk factors in type 2 diabetes: a meta-analysis. Diabetes Care 34 (2011), 1228–1237.
33. [33] Hayashino, Y., Jackson, J.L., Fukumori, N., et al. Effects of supervised exercise on lipid profiles and blood pressure control in people with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials. Diabetes Res Clin Pract 98 (2012), 349–360.
34. [34] Schwingshackl, L., Missbach, B., Dias, S., et al. Impact of different training modalities on glycaemic control and blood lipids in patients with type 2 diabetes: a systematic review and network meta-analysis. Diabetologia 57 (2014), 1789–1797.
35. [35] Colberg, S.R., Sigal, R.J., Fernhall, B., et al. Exercise and type 2 diabetes: the American College of Sports Medicine and the American diabetes association: joint position statement executive summary. Diabetes Care 33 (2010), 2692–2696.
36. Wheeler, M.L., Dunbar, S.A., Jaacks, L.M., et al. Macronutrients, food groups, and eating patterns in the management of diabetes: a systematic review of the literature, 2010. Diabetes Care 35 (2012), 434–445.
37. Ajala, O., English, P., Pinkney, J., Systematic review and meta-analysis of different dietary approaches to the management of type 2 diabetes. Am J Clin Nutr 97 (2013), 505–516.
38. [38] Bosch, J., Gerstein, H.C., Dagenais, G.R., et al. n-3 fatty acids and cardiovascular outcomes in patients with dysglycaemia. N Engl J Med 367 (2012), 309–318.
39. [39] Evert, A.B., Boucher, J.L., Cypress, M., et al. Nutrition therapy recommendations for the management of adults with diabetes. Diabetes Care 37:Suppl 1 (2014), S120–S143.
40. [40] Gepner, Y., Golan, R., Harman-Boehm, I., et al. Effects of initiating moderate alcohol intake on cardiometabolic risk in adults with Type 2 diabetes: a 2-year randomized, controlled trial. Ann Intern Med 163:8 (2015), 569–579.
41. [41] Goff, L.M., Cowland, D.E., Hooper, L., et al. Low glycaemic index diets and blood lipids: a systematic review and meta-analysis of randomised controlled trials. Nutr Metab Cardiovasc Dis 23 (2013), 1–10.
42. [42] Sleiman, D., Al-Badri, M.R., Azar, S.T., Effect of mediterranean diet in diabetes control and cardiovascular risk modification: a systematic review. Front Public Health, 3, 2015, 69.
43. [43] Kelley, G.A., Kelley, K.S., Roberts, S., et al. Efficacy of aerobic exercise and a prudent diet for improving selected lipids and lipoproteins in adults: a meta-analysis of randomized controlled trials. BMC Med, 9, 2011, 74.
44. [44] Wu, T., Gao, X., Chen, M., et al. Long-term effectiveness of diet-plus-exercise interventions vs. diet-only interventions for weight loss: a meta-analysis. Obes Rev 10 (2009), 313–323.
45. [45] Pi-Sunyer, X., Blackburn, G., Brancati, F.L., et al. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care 30 (2007), 1374–1383.
46. [46] Wing, R.R., Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the look AHEAD trial. Arch Intern Med 170 (2010), 1566–1575.
47. Wing, R.R., Bolin, P., Brancati, F.L., et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 369 (2013), 145–154.
48. Franz, M.J., Boucher, J.L., Rutten-Ramos, S., et al. Lifestyle weight-loss intervention outcomes in overweight and obese adults with type 2 diabetes: a systematic review and meta-analysis of randomized clinical trials. J Acad Nutr Diet 115:9 (2015), 1447–1463.
49. [49] Chen, L., Pei, J.H., Kuang, J., et al. Effect of lifestyle intervention in patients with type 2 diabetes: a meta-analysis. Metabolism 64 (2015), 338–347.
50. Schellenberg, E.S., Dryden, D.M., Vandermeer, B., et al. Lifestyle interventions for patients with and at risk for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med 159 (2013), 543–551.
51. [51] Gaede, P., Vedel, P., Larsen, N., et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348 (2003), 383–393.
52. Kearney, P.M., Blackwell, L., Collins, R., et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 371 (2008), 117–125.
53. [53] Colhoun, H.M., Betteridge, D.J., Durrington, P.N., et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the collaborative atorvastatin diabetes study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364 (2004), 685–696.
54. [54] Collins, R., Armitage, J., Parish, S., et al. MRC/BHF heart protection study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361 (2003), 2005–2016.
55. [55] Stone, N.J., Robinson, J.G., Lichtenstein, A.H., et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American college of cardiology/American heart association task force on practice guidelines. J Am Coll Cardiol 63 (2014), 2889–2934.
56. [56] Sattar, N., Preiss, D., Murray, H.M., et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 375 (2010), 735–742.
57. [57] Carter, A.A., Gomes, T., Camacho, X., et al. Risk of incident diabetes among patients treated with statins: population based study. BMJ, 346, 2013, f2610.
58. [58] Erqou, S., Lee, C.C., Adler, A.I., Statins and glycaemic control in individuals with diabetes: a systematic review and meta-analysis. Diabetologia 57 (2014), 2444–2452.
59. [59] Swerdlow, D.I., Sattar, N., A dysglycaemic effect of statins in diabetes: relevance to clinical practice?. Diabetologia 57 (2014), 2433–2435.
60. [60] Bays, H.E., Neff, D., Tomassini, J.E., et al. Ezetimibe: cholesterol lowering and beyond. Expert Rev Cardiovasc Ther 6 (2008), 447–470.
61. [61] Fleg, J.L., Mete, M., Howard, B.V., et al. Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial. J Am Coll Cardiol 52 (2008), 2198–2205.
62. Cannon, C.P., Blazing, M.A., Giugliano, R.P., et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 372 (2015), 2387–2397.
63. [63] Younk, L.M., Davis, S.N., Evaluation of colesevelam hydrochloride for the treatment of type 2 diabetes. Expert Opin Drug Metab Toxicol 8 (2012), 515–525.
64. [64] Ooi, C.P., Loke, S.C., Colesevelam for type 2 diabetes mellitus. Cochrane Database Syst Rev, 12, 2012, CD009361.
65. [65] Lee, M., Saver, J.L., Towfighi, A., et al. Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidaemia: a meta-analysis. Atherosclerosis 217 (2011), 492–498.
66. Ginsberg, H.N., Elam, M.B., Lovato, L.C., et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 362 (2010), 1563–1574.
67. [67] Ding, Y., Li, Y., Wen, A., Effect of niacin on lipids and glucose in patients with type 2 diabetes: a meta-analysis of randomized, controlled clinical trials. Clin Nutr 34 (2015), 838–844.
68. [68] McKenney, J., Bays, H., Gleim, G., et al. Safety and tolerability of extended-release niacin-laropiprant: pooled analyses for 11,310 patients in 12 controlled clinical trials. J Clin Lipidol 9 (2015), 313–325.
69. [69] Villines, T.C., Stanek, E.J., Devine, P.J., et al. The ARBITER 6-HALTS trial (arterial biology for the investigation of the treatment effects of reducing cholesterol 6-HDL and LDL treatment strategies in atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration. J Am Coll Cardiol 55 (2010), 2721–2726.
70. [70] Boden, W.E., Probstfield, J.L., Anderson, T., et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 365 (2011), 2255–2267.
71. [71] Landray, M.J., Haynes, R., Hopewell, J.C., et al. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med 371 (2014), 203–212.
72. [72] Buse, J.B., Tan, M.H., Prince, M.J., et al. The effects of oral anti-hyperglycaemic medications on serum lipid profiles in patients with type 2 diabetes. Diabetes Obes Metab 6 (2004), 133–156.
73. [73] Bolen, S., Feldman, L., Vassy, J., et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med 147 (2007), 386–399.
74. [74] Chaudhuri, A., Dandona, P., Effects of insulin and other antihyperglycaemic agents on lipid profiles of patients with diabetes. Diabetes Obes Metab 13 (2011), 869–879.
75. [75] Deeg, M.A., Buse, J.B., Goldberg, R.B., et al. Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidaemia. Diabetes Care 30 (2007), 2458–2464.
76. [76] Monami, M., Lamanna, C., Desideri, C.M., et al. DPP-4 inhibitors and lipids: systematic review and meta-analysis. Adv Ther 29 (2012), 14–25.
77. [77] Sun, F., Wu, S., Wang, J., et al. Effect of glucagon-like peptide-1 receptor agonists on lipid profiles among type 2 diabetes: a systematic review and network meta-analysis. Clin Ther 37 (2015), 225–241 e8.
78. [78] Ptaszynska, A., Hardy, E., Johnsson, E., et al. Effects of dapagliflozin on cardiovascular risk factors. Postgrad Med 125 (2013), 181–189.
79. [79] Plosker, G.L., Canagliflozin: a review of its use in patients with type 2 diabetes mellitus. Drugs 74 (2014), 807–824.
80. [80] Bennett, W.L., Maruthur, N.M., Singh, S., et al. Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med 154 (2011), 602–613.
81. [81] Guthrie, R.M., Sodium-glucose co-transporter 2 inhibitors and the potential for cardiovascular risk reduction in patients with type 2 diabetes mellitus. Postgrad Med 125 (2013), 21–32.
82. [82] Buchwald, H., Estok, R., Fahrbach, K., et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med 122 (2009), 248–256 e5.
83. [83] Dixon, J.B., O'Brien, P.E., Playfair, J., et al. Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA 299 (2008), 316–323.
84. [84] Schauer, P.R., Kashyap, S.R., Wolski, K., et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med 366 (2012), 1567–1576.
85. [85] Mingrone, G., Panunzi, S., De Gaetano, A., et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med 366 (2012), 1577–1585.
86. [86] Ikramuddin, S., Korner, J., Lee, W.J., et al. Roux-en-Y gastric bypass vs intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidaemia: the diabetes surgery study randomized clinical trial. JAMA 309 (2013), 2240–2249.
87. [87] Schauer, P.R., Bhatt, D.L., Kirwan, J.P., et al. Bariatric surgery versus intensive medical therapy for diabetes–3-year outcomes. N Engl J Med 370 (2014), 2002–2013.
88. [88] Sjostrom, L., Peltonen, M., Jacobson, P., et al. Bariatric surgery and long-term cardiovascular events. JAMA 307 (2012), 56–65.
89. [89] Mihaylova B, Emberson J, Blackwell L, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 380: 581–590.
90. [90] Stroes, E.S., Thompson, P.D., Corsini, A., et al. Statin-associated muscle symptoms: impact on statin therapy-European atherosclerosis society consensus panel statement on assessment, aetiology and management. Eur Heart J 36 (2015), 1012–1022.
91. [91] Barter, P.J., Brewer, H.B. Jr., Chapman, M.J., et al. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol 23 (2003), 160–167.
92. [92] Barter, P.J., Caulfield, M., Eriksson, M., et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 357 (2007), 2109–2122.
93. [93] Schwartz, G.G., Olsson, A.G., Abt, M., et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 367 (2012), 2089–2099.
94. [94] Rader, D.J., deGoma, E.M., Future of cholesteryl ester transfer protein inhibitors. Annu Rev Med 65 (2014), 385–403.
95. [95] Abifadel, M., Varret, M., Rabes, J.P., et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolaemia. Nat Genet 34 (2003), 154–156.
96. [96] Abifadel, M., Elbitar, S., El Khoury, P., et al. Living the PCSK9 adventure: from the identification of a new gene in familial hypercholesterolaemia towards a potential new class of anticholesterol drugs. Curr Atheroscler Rep, 16, 2014, 439.
97. Stein, E.A., Raal, F.J., New therapies for reducing low-density lipoprotein cholesterol. Endocrinol Metab Clin North Am 43 (2014), 1007–1033.
98. [98] Rader, D.J., Human genetics of atherothrombotic disease and its risk factors. Arterioscler Thromb Vasc Biol 35 (2015), 741–747.
99. [99] Schwartz, G.G., Bessac, L., Berdan, L.G., et al. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. Am Heart J 168 (2014), 682–689.